Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade A 40.38 0.57% 0.23
BHVN closed up 0.57 percent on Friday, June 22, 2018, on 1.89 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BHVN trend table...

Date Alert Name Type % Chg
Jun 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jun 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jun 22 NR7 Range Contraction 0.00%
Jun 22 Multiple of Ten Bullish Other 0.00%
Jun 22 Inside Day Range Contraction 0.00%
Jun 21 Upper Bollinger Band Walk Strength 0.57%
Jun 21 Multiple of Ten Bullish Other 0.57%
Jun 20 Bearish Engulfing Bearish -2.32%
Jun 20 Slingshot Bullish Bullish Swing Setup -2.32%
Jun 20 Upper Bollinger Band Walk Strength -2.32%

Older signals for BHVN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 44.28
52 Week Low 16.5
Average Volume 432,897
200-Day Moving Average 30.1767
50-Day Moving Average 32.1978
20-Day Moving Average 37.412
10-Day Moving Average 39.853
Average True Range 1.8423
ADX 38.21
+DI 29.26
-DI 15.74
Chandelier Exit (Long, 3 ATRs ) 38.7531
Chandelier Exit (Short, 3 ATRs ) 38.5369
Upper Bollinger Band 43.0098
Lower Bollinger Band 31.8142
Percent B (%b) 0.77
BandWidth 29.925158
MACD Line 2.6362
MACD Signal Line 2.502
MACD Histogram 0.1342
Fundamentals Value
Market Cap 1.45 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -5.36
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.63
Resistance 3 (R3) 42.57 41.75 42.26
Resistance 2 (R2) 41.75 41.18 41.79 42.13
Resistance 1 (R1) 41.07 40.83 41.41 41.13 42.00
Pivot Point 40.25 40.25 40.43 40.29 40.25
Support 1 (S1) 39.57 39.68 39.91 39.63 38.76
Support 2 (S2) 38.75 39.33 38.79 38.63
Support 3 (S3) 38.07 38.75 38.51
Support 4 (S4) 38.13